Skip to main content
HUAPONT LIFE SCIENCES CO., LTD. logo

HUAPONT LIFE SCIENCES CO., LTD. — Investor Relations & Filings

Ticker · 002004 ISIN · CNE000001JJ6 LEI · 3003009TGXJC0JJVTJ07 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,461 across all filing types
Latest filing 2020-05-27 Legal Proceedings Report
Country CN China
Listing Shenzhen Stock Exchange 002004

About HUAPONT LIFE SCIENCES CO., LTD.

https://www.huapont.com.cn

HUAPONT LIFE SCIENCES CO., LTD. operates as a diversified entity specializing in the research, development, manufacturing, and distribution of pharmaceutical and chemical solutions. The company holds a prominent position in the dermatology sector, providing a comprehensive range of therapeutic products for various skin disorders. Its pharmaceutical operations extend to the production of high-quality active pharmaceutical ingredients (APIs) and finished dosage forms. Beyond human health, the organization maintains a significant footprint in the agrochemical sector, focusing on the development and supply of crop protection products, including herbicides and pesticides. The company also integrates healthcare services into its business model, overseeing the operation of medical facilities and specialized clinics. Its strategic focus centers on technological advancement and the maintenance of a robust supply chain to support its global commercial activities.

Recent filings

Filing Released Lang Actions
重庆源伟律师事务所关于公司分拆所属子公司山东凯盛新材料股份有限公司至深圳证券交易所创业板上市的法律意见书
Legal Proceedings Report Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the spin-off and listing of a subsidiary company (Shandong Kaisheng New Materials Co., Ltd.) of Huabang Life Health Co., Ltd. on the Shenzhen Stock Exchange's Growth Enterprise Market. The document extensively discusses the legal compliance, approvals, qualifications, and conditions related to the spin-off listing, referencing relevant laws, regulations, and audit reports. It is a detailed legal opinion rather than a financial report, earnings release, or management discussion. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a simple announcement or certification but a comprehensive legal opinion document. Therefore, the most appropriate classification is Legal Proceedings Report (LTR), as it relates to legal matters concerning the company's corporate actions and regulatory compliance for the spin-off listing.
2020-05-27 Chinese
独立董事关于分拆所属子公司山东凯盛新材料股份有限公司至创业板上市的独立意见
Board/Management Information Classification · 90% confidence The document is an independent opinion statement from the independent directors of Huabang Life Health Co., Ltd. regarding the spin-off and listing of its subsidiary Shandong Kaisheng New Materials Co., Ltd. on the Shenzhen Stock Exchange's Growth Enterprise Market (创业板). It discusses compliance with laws, governance, and the rationale for the spin-off listing. The document is a formal opinion on a corporate action related to a subsidiary's listing, not a full financial report, earnings release, or regulatory filing. It is not a report publication announcement since it contains substantive content and opinions. This type of document fits best under Board/Management Information (MANG) as it relates to board-level opinions on corporate restructuring and listing matters.
2020-05-27 Chinese
关于本次上市公司分拆子公司上市董事会决议日前股票价格波动是否达到《关于规范上市公司信息披露及相关各方行为的通知》第五条相关标准的说明
Regulatory Filings Classification · 95% confidence The document is a formal announcement by a listed company regarding the stock price volatility before a board resolution on a subsidiary's spin-off listing. It references regulatory standards from the China Securities Regulatory Commission (CSRC) and provides detailed stock price data and comparisons to indices. The document is short (1663 characters) and focuses on compliance with disclosure regulations rather than presenting financial statements or detailed reports. It does not contain financial results, management discussion, or audit information. It is an announcement explaining the stock price movement in relation to regulatory disclosure requirements, which fits best under Regulatory Filings (RNS) as it is a compliance-related disclosure that does not fit other specific categories.
2020-05-27 Chinese
第七届董事会第十六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 16th meeting of the 7th Board of Directors of Huabang Life Health Co., Ltd. It discusses the approval of a plan to spin off a subsidiary, Shandong Kaisheng New Materials Co., Ltd., for listing on the Shenzhen Stock Exchange's ChiNext board. The document includes detailed background, purpose, compliance with regulations, financial data, and governance aspects related to the spin-off and listing. It is a formal board meeting resolution announcement, focusing on corporate governance and management decisions rather than financial results or earnings. There is no indication that this is a full annual or interim report, audit report, earnings release, or investor presentation. The document is not a proxy solicitation or voting results announcement but a board/management information disclosure about corporate actions. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length (over 10,000 characters) and detailed content confirm it is not a brief announcement or report publication notice.
2020-05-27 Chinese
第七届监事会第十二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 12th meeting of the 7th Supervisory Board of Huabang Life Health Co., Ltd. It discusses the company's plan to spin off its subsidiary, Shandong Kaisheng New Materials Co., Ltd., for listing on the Shenzhen Stock Exchange's ChiNext board. The text includes detailed background, purpose, compliance with regulations, financial data, and governance assurances related to the spin-off and listing. It is a formal meeting resolution announcement rather than a full financial report or audit report. The document is not a financial statement, earnings release, or investor presentation, but rather a formal corporate governance announcement about a significant corporate action requiring shareholder approval. Therefore, it fits best under the category of Board/Management Information (MANG), which covers announcements of changes or significant decisions by the company's board or management. The document length (9480 characters) and content support this classification, and it is not merely an announcement of a report publication or a regulatory filing. Hence, the classification is MANG with high confidence.
2020-05-27 Chinese
东海证券股份有限公司关于公司分拆所属子公司山东凯盛新材料股份有限公司至创业板上市之核查意见
Regulatory Filings
2020-05-27 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.